Vicore published FY2018 results that were broadly in line with our forecasts and reflect a c.45% increase in operating expenses as a result of the integration of INIM Pharma (acquired in July 2018). Of note, this is the first set of accounts presented in IFRS (previously K3). The change in accounting standards is a necessary step ahead of the planned up-listing to the Nasdaq Stockholm later this year. The main impact is that R&D costs are no longer capitalised in the balance sheet, but expensed ....
26 Mar 2019
Pipeline on track at FY2018. Moving to IFRS
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pipeline on track at FY2018. Moving to IFRS
Vicore Pharma Holding AB (6Y4:FRA) | 0 0 0.0%
- Published:
26 Mar 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
13
Vicore published FY2018 results that were broadly in line with our forecasts and reflect a c.45% increase in operating expenses as a result of the integration of INIM Pharma (acquired in July 2018). Of note, this is the first set of accounts presented in IFRS (previously K3). The change in accounting standards is a necessary step ahead of the planned up-listing to the Nasdaq Stockholm later this year. The main impact is that R&D costs are no longer capitalised in the balance sheet, but expensed ....